TABLE 1.

Enhancement of DV2 infection by anti-DV1 immune serum in multiple donorsd

Serum no.ADE observed (peak enhancement titer)a
BC266BC284BC287BC291BC295
immDC (25 ± 1.5)bmatDC (10 ± 2.1)bimmDC (28 ± 2.1)bmatDC (12.7 ± 2.7)bimmDC (17 ± 2.0)bmatDC (8.2 ± 1.5)bimmDC (30 ± 1.8)bmatDC (7.7 ± 2.3)bimmDC (17, 22)cmatDC (10, 7.4)c
94501283++ (640)+ (640)+ (640)+ (2,560)+ (640)
94501286++ (640)± (2,560)++ (640)NTNT
94501310+++ (2,560)± (640)+ (2,560)+ (640)
94501326±+ (2,560)+ (640)± (2,560)NTNT
94501333+++ (640)+ (640)+ (2,560)NTNT
  • a ADE responses are indicated as ++(power, >5), +(power, 2 to 5), ±(power, <2), or −(no ADE observed).

  • b The numbers represent the mean percent baseline infection rate (no sera) ± standard deviation calculated from at least three independent infections from each donor.

  • c The two numbers represent the percent baseline infection rates (no sera) from two independent infections.

  • d We planned a 5-by-5-by-2 matrix to test five donors, with five sera across a dilution range (1:10 to 1:163,840), comparing two different cell types (immDC and matDC) for a total of 50 data points. Due to limited cell availability, only 46 of 50 data points are shown. NT, not tested. Experiments were repeated if cells and sera permitted (serum 94501283 was used in repeated experiments for all five donors, and serum 94501333 was used in repeated experiments for four donors).